ArticleScientific reports2026
Utility of mimicking B cell epitopes between Mycobacterium leprae and host as prognostic biomarkers in type 1 reaction in leprosy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mycobacterial infections such as leprosy and tuberculosis can induce autoimmune responses by disrupting host immune homeostasis. We previously identified eight mimicking B cell epitopes (BCEs) with elevated autoantibody levels in Type 1 Reaction (T1R). In this study, we longitudinally evaluated BCE-specific antibody responses and standardized a dot blot assay for T1R detection. A total of 150 untreated leprosy patients were enrolled: 50 each with T1R, Type 2 Reaction (T2R), and non-reactional (NR) cases; however, follow-up of T2R patients was not feasible. Patients were monitored every 3-4 months for changes in antibody profiles. ELISA quantified antibodies against 15 BCEs derived from Mycobacterium leprae (M. leprae) (HSP65, 50 S ribosomal protein, lysyl tRNA synthetase) and host proteins (keratin, myelin basic protein). Dot blot analysis was performed with pooled sera from each group, and cut-off values were derived from NR intensities. Elevated antibodies against HSP2, HSP4-HSP6, KER1, KER2, KER4, MBP50SB1, and MBPLMB2 were strongly associated with T1R and correlated with disease progression in longitudinal analyses. Blot analyses confirmed higher intensities in T1R and T2R compared to NR and healthy controls (HC). Furthermore, future studies with larger longitudinal cohorts and longer follow-up periods are needed to validate these findings and to better characterize changes in autoantibody levels throughout disease progression and treatment, while the identification of these BCEs as potential prognostic biomarkers may also support the adaptation of the dot blot assay into cost-effective lateral flow platforms for clinical screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.